Biochemical and Biophysical Research Communications, Journal Year: 2025, Volume and Issue: unknown, P. 151965 - 151965
Published: May 1, 2025
Language: Английский
Journal of Psychopharmacology, Journal Year: 2024, Volume and Issue: 38(2), P. 162 - 167
Published: Jan. 31, 2024
Background: The N-methyl-D-aspartate antagonist ketamine has rapid onset antidepressant activity in treatment-resistant depression (TRD). Aims: To evaluate mood rating, safety and tolerability data from patients with TRD treated the psychoactive control fentanyl, as part of a larger study to explore EEG biomarkers associated response. Methods: We evaluated efficacy intramuscular racemic 25 TRD, using double-blind active-controlled randomized crossover design. Ketamine doses were 0.5 1 mg/kg, was fentanyl 50 mcg, given at weekly intervals. Results/outcomes: Within h dosing, reported reduced anxiety ratings, which persisted for up 7 days. A dose–response profile noted dissociative side effects, adverse events changes blood pressure; however, ratings broadly similar both doses. Overall, 14/25 (56%) responders (⩾50% reduction 24 compared baseline) either dose Hospital Anxiety Depression Scale (HADS), 18/25 (72%) HADS-anxiety scale. After only 1/25 (HADS-depression) 3/25 (HADS-anxiety) responders. generally safe well tolerated this population. Conclusions: Our findings add literature confirming ketamine’s against depressive symptoms TRD.
Language: Английский
Citations
8
Frontiers in Psychiatry, Journal Year: 2024, Volume and Issue: 15
Published: Feb. 15, 2024
Introduction Psilocybin is a classic psychedelics, which has been shown to have antidepressant effects by many studies in recent years. In this study, we aim evaluate the efficacy, acceptability and tolerability of psilocybin treatment primary (major depressive disorder) or secondary (experiencing distress related life-threatening diagnoses terminal illness) depression. Methods We searched PubMed, EMBASE, Web Science, Cochrane Library ClinicalTrials.gov for clinical trials depression (updated 4 October, 2023). Effect size Hedges’ g was used as an indicator other outcomes included response rate, drop-out adverse events. Results A total 10 were finally systematic review. 8 meta-analysis, involving 524 adult patients, produced large effect favor (Hedge’s =-0.89, 95% CI -1.25~-0.53, I² = 70.19%, P<0.01). The therapeutic increase with increasing doses. Adverse events caused are generally transient reversible, but serious also may occur. Discussion Our study shows that both short-term long-term holds promise potential complementary alternative therapy depression, probably. Further research reveal more about its potential.
Language: Английский
Citations
7
L Encéphale, Journal Year: 2024, Volume and Issue: unknown
Published: Feb. 1, 2024
Citations
7
British Journal of Anaesthesia, Journal Year: 2024, Volume and Issue: unknown
Published: Oct. 1, 2024
Language: Английский
Citations
7
Life, Journal Year: 2023, Volume and Issue: 13(4), P. 1043 - 1043
Published: April 19, 2023
Background: Pramipexole is a dopamine full agonist approved for the treatment of Parkinson’s disease and restless legs syndrome. Its high affinity D3 receptor neuroprotective, antioxidant, anti-inflammatory activity provides rationale depression. In this paper, we review studies on effectiveness safety antidepressant pramipexole augmentation in treatment-resistant Methods: This comprehensive systematic meta-analysis observational pramipexole–antidepressant included patients with resistant unipolar bipolar The primary outcome measure was response, measured at study endpoint. Results: We identified 8 including 281 overall, 57% women 39.5% disorder 60.5% major depressive disorder. mean follow-up duration 27.3 weeks (range 8–69). pooled estimate response 62.5%, without significant differences between Safety good, nausea somnolence most frequent side effects. Conclusions: findings review, needing further confirmation, show that off-label use as could be useful safe strategy
Language: Английский
Citations
15
Expert Review of Clinical Pharmacology, Journal Year: 2023, Volume and Issue: 16(4), P. 349 - 362
Published: March 31, 2023
Deficiencies in standard of care antidepressants are driving novel drug discovery. A new age antidepressant medications has emerged with the introduction rapid-acting efficacy treatment-resistant patients.The newly approved medicines and those clinical development for major depressive disorder (MDD) documented this scoping review emerging antidepressants. Compounds evaluated efficacy, tolerability, safety compared to medicines.A discovery relies heavily on glutamatergic mechanisms. New based upon model ketamine have been delivered development. Rapid onset ability impact depression, raises question best first-line patients. Drugs improvements tolerability being investigated (e.g. mGlu2/3 receptor antagonists, AMPA potentiators, NMDA modulators). Multiple companies working toward identification psychedelic drugs where requirement activity is not fully known. Gaps still exist - methods matching patients specific needed, prevention MDD its disease progression need research attention.
Language: Английский
Citations
14
Frontiers in Psychiatry, Journal Year: 2024, Volume and Issue: 15
Published: Feb. 1, 2024
Psychiatry is in a growth phase which several psychedelic medicines have entered its arena with great promise. Of these, presently, ketamine the only medicine that may be legally prescribed. We hypothesize at subanesthetic doses, produces unique spectrum of altered states, ranging from psychoactive to deep ego-dissolving experiences, are intrinsic ketamine’s therapeutic effects. When these experiences embedded relationship—a setting—that fosters an amplification recipient’s subjective consciousness, personal growth, inner healing, greater clarity, and better relationships well ensue. While much literature on labels dissociative effects as ‘side effects’, alteration consciousness component unavoidable ‘effect’ impact. From inception clinical trials 1960s, was recognized for producing dissociative, subjects they emerged ketamine-induced anesthesia. Unanticipated unintegrated, ‘emergence phenomena’ were felt disturbing. Accordingly, such been typically labeled side However, conducive set settings, demonstrated positive use psychiatry psychotherapy, providing time-out usual states mind facilitate reshaping self-experience along symptomatic relief. In this way, ketamine-assisted psychotherapy (KAP) offers new potential powerfully valanced toward recognizing experience, individuality, imagination. Essential successful experience outcome KAP close attention expression by recipient integration healing opportunity.
Language: Английский
Citations
5
Expert Opinion on Drug Discovery, Journal Year: 2022, Volume and Issue: 17(10), P. 1131 - 1146
Published: Aug. 8, 2022
Major depressive disorder remains a prevalent world-wide health problem. Currently available antidepressant medications take weeks of dosing, do not produce response in all patients, and have undesirable ancillary effects.The present opinion piece focuses on the major inroads to creation new antidepressants. These include N-methyl-D-aspartate (NMDA) receptor antagonists related compounds like ketamine, psychedelic drugs psilocybin, muscarinic scopolamine. The preclinical clinical pharmacological profile these new-age is discussed.Preclinical data accumulated predict next generation medicines. In contrast current standard care drugs, differ that they demonstrate rapid activity, often after single dose, effects outlive their presence brain. also can provide efficacy for treatment-resistant depressed patients. mechanism action suggests strong glutamatergic component involves facilitation AMPA function. Antagonism mGlu2/3 receptors relevant pharmacology this class drugs. Based upon ongoing efforts develop antidepressants, drug approvals are predicted near future.
Language: Английский
Citations
18
Therapeutic Advances in Psychopharmacology, Journal Year: 2023, Volume and Issue: 13
Published: Jan. 1, 2023
Background: In the last few years, ketamine is becoming increasingly common in treatment of mental health conditions, but there a lack safety data informing intramuscular and sublingual dosing community-focused group psychotherapy setting. The Roots To Thrive ketamine-assisted therapy (RTT-KaT) program unique 12-week RTT-KaT with 12 community practice (a form therapy) sessions three medicine sessions. Objectives: This study reports on adverse effects setting among 128 participants across four cohorts. Design: Retrospective chart review. Methods: A review Program was performed retrospectively cohorts ( n = 128) that participated 448 running between September 2020 December 2021. Baseline characteristics events were captured including medication administration before, during, after Analyses by session individual conducted. Chi-square test Yates’ continuity correction used to assess side subgroups from administration. Results: well tolerated none dropping out program. Primarily, sessions, 49.16% had elevated blood pressures post-KaT session. terms other effects, 12.05% participant-sessions experienced nausea, 2.52% an episode vomiting, 3.35% headache, seven dizziness. Analysis revealed congruent findings. Conclusion: These findings suggest good tolerability for individuals seeking issues. majority did not experience reactions recorded involved transient symptoms resolved rest and/or medications. model described provides comprehensive approach presents promising operating KaT
Language: Английский
Citations
10
Biologics, Journal Year: 2025, Volume and Issue: 5(1), P. 7 - 7
Published: March 3, 2025
The molecular regulation and therapeutic applications of brain-derived neurotrophic factor (BDNF)–tropomyosin-related kinase B (TrkB) signaling in major depressive disorder (MDD) through interaction with vascular endothelial growth (VEGF) N-methyl-D-aspartic acid (NMDA) receptors show promise. While BDNF-TrkB is implicated antidepressant action, the association between BDNFs depression has not yielded conclusive results. Some studies decreased BDNF levels depression, while others indicate that increased expression certain brain regions can induce susceptibility. role varies across different regions, necessitating further study individual mechanisms. This regional variability complicates development targeted therapies. antidepressant-like actions require VEGF signaling, but there also a reciprocal interdependence, as are dependent on BDNFs. complex relationship
Language: Английский
Citations
0